Navigation Links
ChartTrends®: Multiple Sclerosis Report Reveals the Latest Approach to the Treatment and Management of MS
Date:11/2/2010

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs).

In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications, prevalence of symptoms and symptomatic treatment), the report provides insight into the factors that drive decisions to initiate treatment and factors that drive DMA brand selection for both first line and switch patients. Profiles for patients treated with each DMA brand (Avonex, Betaseron, Copaxone, Rebif and Tysabri) are provided. There are a number of differences between patients treated with the various DMAs including MRI status, functioning, disease progression, clinical response and likelihood of switching to a pipeline DMA in the future. The most likely patient types for newly approved Gilenya and late-stage DMAs in development (e.g. Movectro, alemtuzumab, daclizumab) are identified. A number of patient characteristics, including disease classification and current DMA brand, influence the likelihood of a potential switch to Gilenya.

Since initiating on their most current DMA, one-third of patients have experienced an exacerbation with the most common symptoms including muscle weakness and gait/coordination issues. While most exacerbations are treated with short steroid pulses, the use of chronic pharmacological treatment is common for management of spasticity, pain syndromes, bladder/bowel dysfunction, depression/apathy and fatigue. The patient types being selected for treatment with Ampyra, the first FDA-approved symptomatic agent for MS launched in March 2010, are identified in the report.

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, Inc. is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com

ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group
2. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
3. ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
6. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
9. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):